EDURAN Trilpivirine — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson EDURAN Trilpivirine — Sales to customers (Note 9) increased by 6.9% to $770.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 16.5%, from $661.00M to $770.00M. Over 2 years (FY 2021 to FY 2024), EDURAN Trilpivirine — Sales to customers (Note 9) shows an upward trend with a 14.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand or successful commercialization, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product EDURANT (ril...
Peer comparison
Comparable to product-specific revenue line items reported by other pharmaceutical companies, often categorized under specialty or infectious disease therapeutic segments.
jnj_segment_edurant_rilpivirine_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $486.00M | $524.00M | $518.00M | $585.00M | $496.00M | $449.00M | $491.00M | $560.00M | $593.00M | $646.00M | $593.00M | $661.00M | $644.00M | $716.00M | $720.00M | $770.00M |
| QoQ Change | — | +7.8% | -1.1% | +12.9% | -15.2% | -9.5% | +9.4% | +14.1% | +5.9% | +8.9% | -8.2% | +11.5% | -2.6% | +11.2% | +0.6% | +6.9% |
| YoY Change | — | — | — | — | +2.1% | -14.3% | -5.2% | +12.9% | +32.1% | — | +5.9% | +11.5% | — | +10.8% | +21.4% | +16.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's eduran trilpivirine — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported eduran trilpivirine — sales to customers (note 9) of $770.00M in Q3 2025.
- How has Johnson & Johnson's eduran trilpivirine — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's eduran trilpivirine — sales to customers (note 9) increased by 16.5% year-over-year, from $661.00M to $770.00M.
- What is the long-term trend for Johnson & Johnson's eduran trilpivirine — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's eduran trilpivirine — sales to customers (note 9) has grown at a 14.9% compound annual growth rate (CAGR), from $1.93B to $2.54B.
- What does eduran trilpivirine — sales to customers (note 9) mean?
- The total revenue earned from selling the drug EDURANT to customers.